



ASX ANNOUNCEMENT

7 September 2015

Cynata to Present at Rodman & Renshaw 17th Annual Global Investment Conference

Cynata Therapeutics Ltd (ASX: CYP) announced today that Dr Ross A Macdonald, Managing Director and Chief Executive Officer at Cynata, will present at Rodman & Renshaw's 17th Annual Global Investment Conference on Wednesday, 9 September 2015 from 2:10 pm to 2:35pm in Astor Suite A (2nd floor), St Regis Hotel, New York City.

Dr Macdonald stated, "It will be a pleasure to present on Cynata during Rodman & Renshaw's 17th Annual Global Investment Conference. The conference always draws a broad range of sophisticated investors, key leaders in the biopharmaceutical industry and potential partners. I look forward to presenting to such a targeted audience."

Dr. Macdonald's presentation will be webcast live: to listen to the presentation, which will be archived for 90 days, please use the following link: <http://wsw.com/webcast/rrshq25/cyp.ax>

CONTACTS:

Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com

Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com

Amit Tandon, Director of Research, SeeThruEquity: +1 (646) 495-0939; amit@seethruequity.com

Kirin Smith, Chief Operations Officer, US Investor Contact, +1 646-863-6519, ksmith@pcgadvisory.com

Sean Leous, Chief Communications Officer, US Media Contact, +1 646-863-8998, sleous@pcgadvisory.com

Emma Power, Monsoon Communications, Australia Media Contact, 0419 149 525, emmap@monsoon.com.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform delivers a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.